Insecticides India Q4 FY26 Revenue Up 19% to ₹426 Crore; FY26 Revenue Grows 7%
Insecticides (India) Limited reported Q4 FY26 revenue of ₹426 crore, a 19% increase year-on-year. For FY26, revenue grew 7% to ₹2,140 crore. The company launched GRANUVIA in May 2026 and strengthened its product portfolio with new launches. Gross profit margins were stable at 31.5% for FY26.
The announcement details solid revenue growth and strategic initiatives like new product launches and collaborations, which are likely to positively influence the company's future performance and investor sentiment.
The company reported strong revenue growth in Q4 FY26 and positive revenue growth for the full FY26, driven by new product launches and strong market traction of key brands, indicating a positive financial performance.
Insecticides (India) Limited (IIL) has announced its audited financial results for the fourth quarter and the full financial year ended March 31, 2026. The company reported a significant 19% revenue growth in Q4 FY26, reaching ₹426 crore, driven by strong performance in both B2B and B2C segments. Premium products saw a robust 24% growth during the quarter.
For the full financial year FY26, IIL registered a 7% revenue growth, amounting to ₹2,140 crore. This growth was attributed to the positive farmer acceptance of newly launched next-generation crop solutions, with key brands like Torry Super, Shinwa, Centran, Sparcle, and Kunoichi showing strong market traction. The company also highlighted its continued collaboration with Corteva Agriscience, including the launch of GRANUVIA in May 2026.
Gross profit margins remained stable at 31.5% for FY26, compared to 32% in FY25. EBITDA stood at ₹26 crore for Q4 FY26, a decrease of 2% from the previous year, and ₹227 crore for FY26, a 3% increase year-on-year. Profit After Tax for Q4 FY26 was ₹12 crore, down 16% from the prior year, and ₹139 crore for FY26, a 2% decrease.
Mr. Rajesh Aggarwal, MD of Insecticides (India) Ltd., commented that the company delivered a steady performance despite a challenging operating environment. He emphasized the strengthening of the innovation-led product portfolio through successful collaborations, including Altair with Nissan Chemical Corporation and Sparcle & Granuvia with Corteva Agriscience. The introduction of B2C products under its subsidiary, Kaeros Research Limited, was also noted to enhance market reach. IIL remains focused on strengthening its product pipeline, expanding strategic collaborations, and enhancing organizational capabilities.
What to do with a filing like this
Insecticides (India) Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Insecticides (India) Limited. Read the original for the full detail.